Clinical trials located in

Bordeaux Cedex

Bordeaux Cedex city is located in France. Currently, 3 clinical trials are being conducted in this city.

  • CT-EU-00117038


    This is a Phase 1/2 clinical trial looking at a new investigational drug called CFT1946 for treating certain types of solid tumors that have a specific genetic mutation called BRAF V600. This includes cancers like melanoma, non-small cell lung cancer, colorectal cancer, and a type of thyroid cancer called anaplastic thyroid cancer.

    In the first part of the study, called Phase 1, the main goals are to determine the highest safe dose of CFT1946 that can be given and to look at side effects. CFT1946 will be given by itself (monotherapy) or combined with two other approved drugs, trametinib or cetuximab.

    If safe doses are found in Phase 1, the study will then move to Phase 2. In this part, the main goals are to see if the treatments shrink tumors, measured by overall response rate and disease control rate, and how long any responses last, called duration of response.

    The study involves taking CFT1946 and possibly the other drugs by mouth or intravenously on a set schedule, along with regular monitoring, scans, and blood tests. Participation could last up to around 43 months.

    • CFT1946
    • Trametinib
    • Cetuximab
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Study of asciminib dosing and safety in pediatric patients with Chronic Myeloid Leukemia

    This study is designed to determine the appropriate dosing and assess the safety of the drug asciminib for children and teenagers who have a specific type of leukemia called Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML-CP). These patients have previously been treated with at least one other medication known as a tyrosine kinase inhibitor (TKI). The study involves giving different doses of asciminib to see how well the drug works and how safe it is in young patients. The study will enroll participants into two age groups and will follow them over a five-year period to observe the effects of the treatment.

    • Asciminib

See more clinical trials in other cities in France: